Fulcrum Therapeutics, Inc.
FULC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001680581
No open-market purchases or sales by Fulcrum Therapeutics, Inc. insiders were filed in the last 90 days; 154 institutions reported holding it in 13F filings for Q2 2026, worth $291.3M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 10, 2026
- $283.8M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −14 vs. previous quarter
- 154
- 13F valueReported value at the end of Q2 2026
- $291.3M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $0
- −100.0% year over year
- Net income, FY2025
- -$74.9M
- No comparable prior period
- Free cash flow, FY2025
- -$60.4M
- No comparable prior period
- Revenue, Q2 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 6.76M
- Shares sold short
- Change
- −354.3K
- −5.0% vs. previous
- Days to cover
- 4.73
- At average daily volume
Superinvestors holding FULC, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding FULC at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Fulcrum Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 20, 2026 (view filing)9:10 PM ET | Jul 16-17 | 4 days | Tang Kevin C and 1 other10% Owner | PPurchase | +167.6K | $3.55 | +$594.7K | +2.4%7.08M after | 2 lots |
| Jul 15, 2026 (view filing)7:50 PM ET | Jul 13-15 | 2 days | Tang Kevin C and 1 other10% Owner | PPurchase | +249.9K | $3.57 | +$891.1K | +3.8%6.91M after | 4 lots |
| Jun 30, 2026 (view filing) | Jun 26 | 4 days | Ezekowitz AlanDirector | SSale | −18.0K | $3.65 | −$65.7K | −62.2%10.9K after | |
| Feb 4, 2026 (view filing) | Jan 2 | 33 days | Gould Robert JDirector | SSale | −15.0K | $10.87 | −$163.1K | −3.1%469.9K after | Amended |
| Feb 4, 2026 (view filing) | Feb 2 | 2 days | Gould Robert JDirector | SSale | −15.0K | $10.72 | −$160.8K | −3.2%454.9K after | |
| Dec 17, 2025 (view filing) | Dec 15 | 2 days | Oltmans Curtis GaleChief Legal Officer | SSale | −3.45K | $12.92 | −$44.6K | −25.2%10.3K after | |
| Dec 10, 2025 (view filing)4:42 PM ET | Dec 8 | 2 days | RA Capital Healthcare Fund LP and 3 others10% Owner | SSale | −4.18M | $13.98 | −$58.4M | −40.8%6.05M after | 3 lots |
| Nov 21, 2025 (view filing) | Nov 19 | 2 days | Gould Robert JDirector | SSale | −15.0K | $11.03 | −$165.4K | −3.0%484.9K after | |
| May 9, 2025 (view filing) | May 8 | 1 day | Tourangeau GregPrincipal Accounting Officer | SSale | −498 | $5.06 | −$2.52K | −3.4%14.1K after | |
| May 9, 2024 (view filing) | May 7 | 2 days | Tourangeau GregPrincipal Accounting Officer | SSale | −236 | $7.76 | −$1.83K | −2.0%11.6K after |
Top 10 13F holders, Q2 2026
See all 154 holdersThe largest institutional positions in Fulcrum Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8,824,259 | $32.3M | 0.00% | +3,433,666+63.7% | Added |
| EcoR1 Capital, LLC | 6,549,866 | $24.0M | 1.19% | +6,549,866 | New |
| Tang Capital Management LLC | 6,521,412 | $23.9M | 1.08% | +6,521,412 | New |
| Nantahala Capital Management, LLC | 5,475,040 | $20.0M | 1.21% | +2,425,000+79.5% | Added |
| Suvretta Capital Management, LLC | 3,680,921 | $13.5M | 0.28% | −2,880,190−43.9% | Reduced |
| D. E. Shaw & Co., Inc. | 3,044,385 | $11.1M | 0.01% | +1,421,104+87.5% | Added |
| Citadel Advisors LLC | 2,704,505 | $9.90M | 0.01% | +1,412,019+109.2% | Added |
| Vanguard Capital Management LLC | 2,697,216 | $9.87M | 0.00% | +4,268+0.2% | Added |
| Jane Street Group, LLC | 2,217,498 | $8.12M | 0.01% | +1,907,081+614.4% | Added |
| State Street Corp | 2,037,025 | $7.46M | 0.00% | +487,174+31.4% | Added |
Holders of 5% or more of FULC
See all 6 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Fulcrum Therapeutics, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Tang Capital Management LLC | 13G/A | 10.40%6.91M shares | +2.20 ppfrom 8.20% | Jun 10, 20262 filings | Jul 15, 2026 | SEC |
| EcoR1 Capital, LLC | 13G | 9.00%6.00M shares | 0.00 ppfrom 9.00% | Jun 25, 20262 filings | Jun 25, 2026 | SEC |
| Nantahala Capital Management, LLC | 13G | 8.22%5.48M shares | +3.64 ppfrom 4.58% | Nov 14, 20243 filings | Aug 14, 2026 | SEC |
| BlackRock Portfolio Management LLC | 13G/A | 8.10%6.16M shares | +2.10 ppfrom 6.00% | Jul 17, 20262 filings | Oct 27, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 7.20%4.80M shares | +1.20 ppfrom 6.00% | Oct 21, 20246 filings | Jul 28, 2026 | SEC |